Neuroscience & CNS

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research . The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

ABX-CRO operates as an independent full-service contract research organisation with a declared specialism in neuroscience, oncology and molecular imaging, applying a translational medicine approach to take compounds from early bench research through to clinical bedside application. The organisation's formal name, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, reflects its German origins, and its footprint has expanded internationally through both organic growth and strategic acquisitions. The service portfolio spans the full drug development continuum. On the clinical side, ABX-CRO provides radiopharmaceutical clinical trials , clinical operations, medical monitoring, pharmacovigilance, data management and biostatistics. Complementing these, the organisation offers imaging and dosimetry services alongside regulatory affairs support, preclinical and pharmacy capabilities, and project design and strategy consultancy. Medical device studies are also within scope. Several milestones mark the company's recent expansion. ABX-CRO acquired ClinSmart LLC, a Pennsylvania-based clinical quality CRO described as well-established, extending its North American presence. In India, the company secured official registration and accreditation with CDSCO as a radiopharmaceutical CRO , enabling it to conduct radiopharmaceutical clinical trials in that market. Recognition from the scientific community has also followed: ABX-CRO and Isotope Technologies Munich jointly received the Marie Curie Award from the European Association of Nuclear Medicine (EANM), acknowledging their collaborative work in the nuclear medicine field. The organisation additionally maintains an India office and a jobs programme, indicating sustained operational investment across multiple geographies. Further information is available at abx-cro.com.

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Addex Therapeutics is a clinical-stage pharmaceutical company advancing an emerging class of orally available small molecule drugs known as allosteric modulators , targeting neurological disorders and other indications with significant unmet need. Headquartered in Switzerland, the company combines a proprietary technology platform with a diversified pipeline spanning both clinical and pre-clinical programmes. Allosteric modulation, the mechanism at the heart of Addex's research, works by binding to sites on a receptor that are distinct from the primary active site. This approach offers potential advantages in selectivity and tolerability compared with conventional orthosteric drug design, making it a focus of growing interest in CNS drug discovery. The company's pipeline includes Dipraglurant, an mGlu5 negative allosteric modulator being evaluated for post-stroke and traumatic brain injury recovery, alongside ADX71149, an mGlu2 positive allosteric modulator developed in partnership with external collaborators. Two further GABAB positive allosteric modulator programmes address substance use disorder and chronic cough , extending the platform's reach beyond strictly neurological indications into respiratory disease. Addex supports its development activities through strategic partnerships and collaborations, which play a central role in advancing individual pipeline assets. The company is listed on the SIX Swiss Exchange and files with the SEC, maintaining US American Depositary Share (ADS) holders alongside European shareholders. Further information is available at addextherapeutics.com.

Founded in 2018 by Professor Steve Jackson in partnership with Ahren Innovation Capital, Adrestia Therapeutics was a Cambridge-based biotech that pioneered a novel approach to treating intractable genetic diseases through what it called synthetic rescue. The company's Disease Rebalancing Platform mapped gene interaction networks across the human genome to identify molecular partners capable of restoring function in damaged, diseased, or dying cells, creating a systematic atlas of therapeutic opportunities that conventional target-selection methods could not reach. Therapy Areas and Pipeline Adrestia concentrated its early programmes on neurological, neuromuscular, and cardiomyopathic diseases. A notable collaboration with Dr Sarah Tabrizi at University College London focused on Huntington's disease, while a partnership with Proteros Biostructures in Munich accelerated the identification of first-in-class small-molecule candidates across multiple targets. The company also engaged Proteros to support structural biology and drug-discovery chemistry for its lead programmes. Partnerships and Acquisition GSK co-led Adrestia's Series A financing alongside Ahren Innovation Capital, establishing a multi-project discovery collaboration in which each of up to five joint programmes was eligible for up to $230 million in post-option development and commercialisation milestones, plus royalties. In August 2023, Insmed Incorporated (Nasdaq: INSM) acquired Adrestia, integrating its synthetic rescue technology into Insmed's early-stage rare disease research portfolio. Further information is available at adrestia.com.

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company , headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey. The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy . The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval. The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities. Further information is available at amo-pharma.com.

Astex Pharmaceuticals applies its proprietary Pyramid Discovery Platform to the identification and development of drug candidates in oncology and central nervous system (CNS) disorders. Operating at the intersection of cutting-edge technology and translational science, the company has assembled research and development teams focused on generating innovative solutions to the complex challenges that characterise both cancer biology and CNS disease. The company has built a broad product portfolio spanning preclinical and clinical stages. Collaboration and licensing agreements with major pharmaceutical companies underpin part of that portfolio, and three partnered products have reached regulatory approval and are now available on the market. This track record of advancing candidates from discovery through to approved medicines reflects the depth of the company's drug discovery capabilities. Oncology and CNS Research Focus Astex's pipeline addresses two of the most challenging and resource-intensive areas of modern medicine. The oncology and CNS drug discovery programmes draw on proprietary technology to identify novel targets and chemical matter, with candidates progressing through preclinical characterisation into clinical evaluation. The organisation also supports early-career scientists through a postdoctoral research programme, reinforcing its commitment to sustaining innovation over the long term. Headquartered in the United Kingdom, Astex operates as a dedicated pharmaceutical research company with a clinical pipeline that continues to expand alongside its partnered development activities. Strategic partnering remains a core element of its business model, enabling the company to advance multiple assets in parallel with major industry collaborators. Further information is available at astx.com.

Founded by Paul Janssen in Beerse, Belgium in 1953 and now operating as the pharmaceutical division of Johnson Johnson, Janssen Global stands among the world's foremost research-driven pharmaceutical organisations. The business concentrates scientific and commercial resources on discovering, developing and delivering transformative medicines across oncology, immunology, infectious diseases and neuroscience, with a particularly strong record in haematological malignancies and autoimmune conditions. Therapeutic Focus and Pipeline Depth Janssen's approved portfolio illustrates the breadth of its therapeutic reach. In oncology and haematology , Darzalex (daratumumab) has become a standard-of-care option across multiple myeloma lines, while Imbruvica (ibrutinib), developed in collaboration with AbbVie, is approved across several B-cell malignancies. Zytiga (abiraterone acetate) remains a recognised treatment in metastatic prostate cancer. In immunology, Stelara (ustekinumab) and Tremfya (guselkumab) address moderate-to-severe plaque psoriasis and other inflammatory conditions. The neuroscience portfolio includes Spravato (esketamine), a nasal-spray formulation approved for treatment-resistant depression in adults. HIV and tuberculosis medicine reflects a long-standing infectious disease commitment carried through products such as Edurant (rilpivirine) and contribution to combination regimens used globally. Global Operations and Research Infrastructure Research and development hubs span Beerse, Spring House (Pennsylvania), La Jolla (California), Leiden in the Netherlands and Shanghai, supporting a pipeline that extends from early discovery through late-stage clinical programmes. Janssen works alongside academic medical centres, biotech partners and health systems to accelerate access. As a central component of Johnson Johnson's pharmaceutical segment, operating under the J J Innovative Medicine banner from 2023, the organisation benefits from the group's global manufacturing network, regulatory infrastructure and substantial annual R D investment. Its pharmaceutical pipeline spans both small molecules and large biologics, with active programmes in areas such as solid tumours, multiple sclerosis and pulmonary arterial hypertension. Further information is available at janssen.com.

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology , haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.